Favourable safety profile for apricitabine in HIV-1 infections

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1652, 2008-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Atazanavir shows durable efficacy, favourable lipid profile in HIV infections

Inpharma, Vol. 1, Iss. 1381, 2003-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Apricitabine is an effective and tolerable treatment for HIV-1 infection

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Multiple-Dose Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with HIV-1 Infection

By Cahn Pedro

Clinical Drug Investigation, Vol. 28, Iss. 2, 2008-01 ,pp. : 129-138

Adis International

Access to resources Recommend Favorite

Raltegravir raises the BENCHMRK for treating HIV-1 infections

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

HIV-1 infections intervention in Uganda inadequate

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 401, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite